What type of study is this?

December 8, 2025BloodOpen Access

Dexamethasone for management of cytokine release syndrome (CRS) associated with talquetamab in patients with Relapsed/Refractory multiple myeloma

View Full Paper

Ask AI

Bookmark

Authors

KJKelley JulianUniversity of Utah JSJordan Snyder MRMikhaila Rice

Discussion

Member takes

Implication

Retrospective study shows dexamethasone effectively manages cytokine release syndrome in relapsed/refractory multiple myeloma, highlighting its feasibility over tocilizumab.

Key Points

Dexamethasone was used effectively for cytokine release syndrome management in 211 patients with relapsed/refractory multiple myeloma, resulting in notable outcomes.
Among patients treated, 61% experienced cytokine release syndrome, with most cases being manageable grades 1 and 2 after dexamethasone treatment.
Treatment involved pre-medication and varying doses of dexamethasone and tocilizumab, adhering to institutional protocols, with assessed outcomes using IMWG criteria.
Higher recurrence rates of low-grade cytokine release syndrome were noted in the dexamethasone first group, suggesting the need for strategic treatment planning.

Cite This Study

Julian et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e4cb https://doi.org/10.1182/blood-2025-720

View Full Paper

Ask AI

Bookmark

Implication

Retrospective study shows dexamethasone effectively manages cytokine release syndrome in relapsed/refractory multiple myeloma, highlighting its feasibility over tocilizumab.

Dexamethasone for management of cytokine release syndrome (CRS) associated with talquetamab in patients with Relapsed/Refractory multiple myeloma

Discussion

Member takes

Implication

Key Points

Cite This Study

Dexamethasone for management of cytokine release syndrome (CRS) associated with talquetamab in patients with Relapsed/Refractory multiple myeloma

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider